Is 10x Genomics Inc (TXG) Holding Up Well Over a Long-Time Horizon?

At the time of writing, 10x Genomics Inc [TXG] stock is trading at $14.67, down -0.41%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TXG shares have gain 1.77% over the last week, with a monthly amount glided 4.68%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

From an analyst’s perspective:

10x Genomics Inc [NASDAQ: TXG] stock has seen the most recent analyst activity on September 03, 2024, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $35. Previously, Jefferies upgraded its rating to Buy on July 22, 2024, and kept the price target unchanged to $24. On July 18, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $20 on the stock. Deutsche Bank downgraded its rating to a Hold and decreased its price target to $25 on July 10, 2024. Wolfe Research downgraded its rating to a Peer Perform. Guggenheim downgraded its rating to Neutral for this stock on June 25, 2024.

For the past year, the stock price of 10x Genomics Inc fluctuated between $12.95 and $57.78. Currently, Wall Street analysts expect the stock to reach $31.75 within the next 12 months. 10x Genomics Inc [NASDAQ: TXG] shares were valued at $14.67 at the most recent close of the market. An investor can expect a potential return of 116.43% based on the average TXG price forecast.

Analyzing the TXG fundamentals

According to 10x Genomics Inc [NASDAQ:TXG], the company’s sales were 629.74M for trailing twelve months, which represents an -1.30% plunge. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -0.28%, Pretax Profit Margin comes in at -0.28%, and Net Profit Margin reading is -0.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.25 and Total Capital is -0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.51 points at the first support level, and at 14.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.91, and for the 2nd resistance point, it is at 15.15.

Ratios To Look Out For

It is important to note that 10x Genomics Inc [NASDAQ:TXG] has a current ratio of 4.90. In addition, the Quick Ratio stands at 4.12 and the Cash Ratio stands at 3.28. Considering the valuation of this stock, the price to sales ratio is 2.81, the price to book ratio is 2.46.

Transactions by insiders

Recent insider trading involved Saxonov Serge, Chief Executive Officer, that happened on Nov 22 ’24 when 6693.0 shares were sold., Hindson Benjamin J. completed a deal on Nov 22 ’24 to sell 5807.0 shares. Meanwhile, Officer Hindson Benjamin J. bought 5734.0 shares on Nov 22 ’24.

Related Posts